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The comparatIve In vItro and In VIVO activity of 
antilymphocyte serum 
raised by immunization 
with thymic, splenic, 
and lymph node 
lymphocytes 
Although =tilymphocyte "'mm (ALS) 
and antilymphocyte globulin (ALG) have 
been used extensively in clinical organ trans-
plantation, the methods used to prepare 
and assay these agents have not yet been 
well standardized. For example, it has fre-
quently been speculated that the immuno-
suppressive qualities of an ALS might vary 
significantly depending upon the type of 
lymphoid tissue used to immunize the heter-
ologous serum donor.i, 2, 5, 9, 11 
In the present study this hypothesis has 
been examined by comparing the ability of 
rabbit antilymphocyte sera raised against 
splenic, thymic, and lymph node lymphocytes 
to prevent the rejection in rats of hetero-
topically transplanted cardiac homografts. 
The antisera proved to have essentially iden-
tical immunosuppressive potencies. However, 
there were significant differences in the side 
effect of thrombocytopenia which was most 
consistently and markedly produced by the 
antispleen serum. 
METHODS 
Raising of ALS. The lymphoid tissue was 
taken from inbred Fischer (Fi) * rats 
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(AgB 1/1) and was divided into tiny 
pieces by microdissection under normal sa-
line. The cells were removed by passing them 
through a stainless steel mesh (60 denier) 
and a glass wool filter. The composition of 
the eventual antigen suspensions is given in 
Table I. It will be noted that the material 
derived from the spleen contained the great-
est number of thrombocytes. 
The cell suspensions were intravenously 
injected once a week for 4 weeks into 18 
white New Zealand rabbits which were sep-
arated into three groups of six according to 
the lymphoid antigen being used. Each rab-
bit received the same number of lymphocytes 
in the course of the immunization, totaling 
1.3 X 109 cells. Serial leukoagglutinin titers 
were obtained during this interval, and at its 
end the rabbits were bled by cardiac punc-
ture. The sera from the three groups of six 
rabbits were pooled and decomplemented by 
heating at 56° C. for 30 minutes. 
Absorption. The decomplemented anti-
sera were first absorbed with one-third 
volume triply washed and packed rat eryth-
rocytes. The three red cell absorbed pools 
were then each divided; half of the serum 
was used for definitive testing without fur-
ther alteration. The other half in each sub-
group was absorbed 3 times with platelets 
utilizing 5 x 108 , 2.4 X 108, and 12 x 108 
platelets per milliliter of serum. The mixtures 
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Table I. Cellular composition of antigen suspensions used for immunization 
Differential counts (%) 
Rat cell suspensions Small lymph Large lymph ThrombocJ,tes/I0 6 WBe 
Spleen 
Thymus 
90-94 3-5 12,500 
7,250 
2,000 
93-97 3-7 
Lymph node (submaxillary 
and mesenteric) 
90-92 8-10 
of sera and platelets were left standing at 4° 
C. overnight in the first absorption but were 
gently agitated overnight during the second 
and third absorptions. 
By this stage, six test sera were ready. In 
addition, normal rabbit serum (NRS) was 
collected for control studies; it was heated, 
and stored in the same manner as described 
but it was not absorbed with rat erythrocytes 
and thrombocytes. 
In vitro assay. Lymphoagglutinin and 
thromboagglutinin titers were determined by 
placing 0.025 m!. of the serially diluted 
sera with the same volume of a lymph node 
lymphocyte (2 x 107 per milliliter) or throm-
bocyte (4 x 108 per milliliter) suspension. 
The mixture was made in a microtiter 
plate. Lymphoagglutination was read after 
2.5 hours' incubation at 37° C. and throm-
boagglutination after 6 hours. Thymoag-
glutination titers were determined by the 
double dilution tube method. Thymocyte 
suspensions (1 X 107 per milliliter) of 0.1 
m!.) were mixed with 0.1 m!. undiluted or 
diluted ALS in each tube and incubated at 
37° C. for 60 minutes. All agglutination tests 
were considered as positive only if more 
than half of the cells were clumped. Lym-
phocytotoxicity was measured by the dye 
exclusion technique described elsewhere. 6 
In vivo assay. The effects of each of the 
seven different rabbit sera were measured in 
five young outbred Sprague-Dawley rats.* 
The rats were given intraperitoneal injec-
tions of 0.5 m!. on Days 0 and 2 and 1.0 
ml. on Day 4. Rats were bled from the tail 
on Days 0, 1, 3, 5, 8, and 11, and red cell, 
total and differential white cell, and throm-
bocyte counts were determined. In addition 
the animals were weighed after each bleed. 
*Sprague.Dawley, Inc., Madison, Wis. 53711. 
The donors for the cardiac homografts 
were inbred adult Wistar-Furth (WF) rats* 
(AgB2/2). The aorta and pulmonary artery 
of the transplanted hearts were attached to 
the abdominal aorta and inferior vena cava, 
respectively, of the adult recipients by a 
previously described technique.7 The adult 
recipients were all of the Fischer (AgB 1/1) 
strain. They were given 1.0 ml. intra-
peritoneal serum injections on Days 0, 2, and 
5. Graft function was assessed by daily pal-
pation and by biweekly electrocardiograms. 
Graft rejection was taken as complete ab-
sence of electrical activity of the transplant. 
RESULTS 
The serum titers. The antilymphocyte ac· 
tivity of all six test sera was exactly the 
same (Table II). However, there were sig-
nificant differences in the thromboagglutinin 
titers. The highest antiplatelet activity was 
in the ALS that had been raised with splenic 
antigen (Table II). The anti thrombocyte 
titers were reduced by the triple platelet ab-
sorption without affecting the antilympho-
cyte activity (Table II). 
In vivo effects. There was no difference 
among the six test antisera in their effects 
on the white counts. The total lymphocyte 
counts were depressed immediately after the 
first intraperitoneal injection and did not 
begin to recover until many days after the 
last dose was given (Fig. 1). There was also 
a significant fall of the total white count of 
which most was accounted for by the loss 
of lymphocytes (Fig. 1). However, there 
was also a slight depression of the granulo-
cyte counts. 
The three unabsorbed test sera had vari-
able effects on the circulating platelets. The 
*Microbiological Associates, Inc., Bethesda, Md. 20014. 
700 Ona et al. 
Table II. In vitro activity of rabbit antirat lymphoid cell serum 
Sera Lymphoagglutinin Thymoagglutinin Lymphocytotoxicin 
RARSS* 1: 1,000 1: 1,000 1:512 
RARTSt 1: 1,000 1: 1,000 1:512 
RARLNSt 1: 1,000 1: 1,000 1:512 
RARSS-Abs.§ 1: 1,000 1: 1,000 1:512 
RARTS-Abs. 1: 1,000 1: 1,000 1:512 
RARLNS-Abs. 1: 1,000 1: 1,000 1:512 
*RARSS-rabbit antirat spleen cell serum. 
tRARTS-rabbit antirat thymus cell serum. 
tRARLNS-rabbit antirat lymph node cell serum. 
§Abs.-absorbed with rat thrombocytes. 
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Fig. 1. The effect of normal, antithymic, antisplenic, and antilymph node sera on the total 
peripheral white ceH counts and the lymphocyte counts of Sprague-Dawley rats. The antisera 
were raised in rabbits. 
ALS raised with spleen caused the most 
profound thrombocytopenia. The antithymo-
cyte serum caused almost as severe changes. 
The antilymph node serum had the least 
effect (Fig. 2). After absorption with plate-
lets, none of the ALS's produced thrombo-
cytopenia (Fig. 2). 
An interesting finding was the discrepancy 
of the body weight gain of rats treated with 
the various sera. The animals treated with 
NRS gained 53 percent body weight for 11 
days, while other groups had 21 to 36 per-
cent gain. The rats given ALS raised with 
splenic antigen had diarrhea for several days 
and their weight gain was only 21 percent. 
Cardiac transplantation. In the rats 
treated with normal rabbit serum, the heter-
otopic cardiac grafts remained viable for a 
mean of 12 days. In contrast, the trans-
planted hearts in animals treated with ALS 
had a mean survival of more than a month 
(p < 0.001). There was no significant dif-
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Table III, Survival of rat heart allografts treated with rabbit antirat lymphoid 
cell sera 
Sera 
Spleen 
Thymus 10 
Lymph node 10 
Nonnal rabbit serum 10 
Range 
(days) 
28-41 
28, 30, 30, 33, 33, 34, 35, 37, 38, 41 
20-40 
20, 23, 24, 27, 33, 34, 35, 38, 39, 40 
27-46 
27, 30, 31, 31, 34, 39, 41, 41, 44, 46 
9-15 
9, 10, 10, 11, 12, 12, 13, 13, 15, 15 
Mean S.D. (S.E.) 
(days) 
33.9:': 3.9 (1.3) 
31.3:':6.7 (2.4) 
36.4 :!: 6.3 (2.2) 
12.0:!:1.9 (0.7) 
p Value 
p<O.OOI 
p<O.OOI 
p<O.OOI 
Recipient rats were given 1 ml. of each serum on Days 0, 2, and 5 intraperitoneally. 
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Fig. 2. A comparison of the platelet depressing effect of different kinds of rabbit antirat ALS 
(left). On the right are repeat studies after the different kinds of ALS had been absorbed 
with rat platelets. The test animals were Sprague-Dawley rats. 
ference in the protection of the transplants 
by antisera raised with thymic, splenic, or 
lymph node antigen (Table III). 
DISCUSSION 
There were three features of the protocol 
in this study which made it possible to com-
pare the qualities of different kinds of ALS 
with a high degree of accuracy. The first 
was that the use of a controlled inbred rat 
strain (Fi) as the sale source of lymphoid 
tissue for the rabbits assured genetic ho-
mogeneity of the immunizing antigen, Sec-
ond, the immunologic barrier across which 
the transplantations were carried out was a 
well-defined one (AgB 2/2 ~ AgB 1/1) 
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which is comparable to the H-2 system in 
mice. Consequently, the data in both the 
control and treated recipients were highly 
reproducible. Finally, the difficulty often 
encountered with skin grafts in defining the 
exact time of rejection was eliminated. 
There was no equivocation about when the 
heterotopic hearts ceased to beat and to 
emit organized electrical activity. 
The results obtained under these con-
ditions provided no evidence whatever that 
a heterologous ALS with inherently supe-
rior immunosuppressive properties could be 
raised with any particular kind of lymphoid 
tissue. On the contrary, the lymphopenic 
effects of the antithymic, antisplenic, and 
antilymph node sera were almost identical' 
Moreover, the ability of the agents to fore-
stall rejection of auxiliary heart grafts did 
not differ significantly. 
Nevertheless, the experiments emphasized 
that the need for troublesome absorption 
procedures was influenced by the tissue used 
for immunization of the rabbits. When 
spleens were used, undesirable antiplatelet 
antibodies were evoked in the highest titer. 
This effect was somewhat less with thymuses 
and it was barely discernible with lymph 
nodes. As Kashiwagi and associates3, 10 have 
also reported, the thromboagglutinins could 
be removed from ALS by absorption proce-
dures without demonstrably affecting the 
antiwhite cell titers. However, the number 
of platelets required for this purpose was 
so large that a considerable expense would 
be involved for the commercial production 
of bulk quantities of the antisera. 
The thrombocytopenia produced in rats 
when the unabsorbed antispleen and anti-
thymus antisera were given intra peritoneally 
was not serious enough to adversely affect 
the results after cardiac transplantation. The 
reason apparently was that the therapeutic 
course was limited to only three injections 
in 5 days. During this interval or afterward 
obvious bleeding diatheses were not ob-
served. 
In clinical practice, the implications of 
platelet depression have been less trivial in 
patients receiving ALG prepared with sple-
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nic antigen. In a trial in which it was at-
tempted to give the immune horse globulin 
daily in large quantities for several weeks 
after renal transplantation in an effort to 
produce early tolerance, the limitations of 
permissible dosage were imposed by the ex-
tent of the induced thrombocytopenia. 10 
When this complication occurred, it was 
necessary to reduce both the frequency and 
volume of the planned injections. The con-
sequent need to give the ALG as intermit-
tent therapy rather than continuously was 
particularly disquieting since the "pulse" 
technique is known to increase the rapidity 
of sensitization of the treated subject to the 
foreign protein and to therefore shorten the 
period of the immunosuppressive efficien-
cy.4,6 
It may be that some degree of platelet 
depression must be accepted as the in-
herent penalty for high dose ALG treat-
ment since studies from both the Munich 
laboratories of Pichlmayr and associates8 
and our own10 have shown the cross-reactiv-
ity of platelets and lymphocytes to ALS. 
However, the data in the present study sug-
gest that the predominant thrombocytopenic 
effect of an ALS is due to thromboagglu-
tinins caused by platelets which were acci-
dentally included with the immunizing lym-
phocytes. 
It follows that there are two specific mea-
sures which can be taken to decrease the 
thrombocytopenic effect of the ALS raised 
for human use. The most obvious is to take 
special pains to remove the platelets as com-
pletely as possible from the cell suspensions 
administered to the heterologous serum 
donor. Elimination of these platelets can be 
accomplished by filtration, differential cen-
trifugation, and other mechanical means. In 
addition, it is of the utmost importance to 
check the ALS for antiplatelet activity be-
fore the globulin extraction stage is begun. 
Even if a seemingly insignificant activity is 
found, absorption should be carried out with 
platelets since thrombocytopenia has been 
caused in patients with ALG that had 
thromboagglutinin titers as low as 1 :4. In 
the present study, immediate platelet de-
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pressions occurred with antisera that had 
thromboagglutinin titers of 1 :32 or less. 
SUMMARY 
Rabbit ALS was raised against the sple-
nic, thymic, and lymph node lymphocytes of 
inbred Fischer rats. The different antisera 
had the same ability to induce lymphopenia 
or to protect auxiliary cardiac homografts 
from rejection after transplantation from 
Wistar-Furth donors to Fischer recipients. 
There was a difference in the toxicity of the 
agents in that the antispleen and anti thymus 
sera caused thrombocytopenia. The severity 
of this complication seemed related to the 
degree of platelet contamination of the rat 
cell suspensions originally given to the rab-
bits. The thrombocytopenia can be at least 
partially avoided by cleaning up the im-
munizing antigen as well as by platelet ab-
sorption of the resulting ALS. 
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